176 related articles for article (PubMed ID: 23679932)
1. Transarterial chemoembolization of hepatocellular carcinoma--agents and drugs: an overview. Part 2.
Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G
Expert Opin Drug Deliv; 2013 Jun; 10(6):799-810. PubMed ID: 23679932
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1.
Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G
Expert Opin Drug Deliv; 2013 May; 10(5):679-90. PubMed ID: 23406440
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.
Tsochatzis EA; Germani G; Burroughs AK
Semin Oncol; 2010 Apr; 37(2):89-93. PubMed ID: 20494700
[TBL] [Abstract][Full Text] [Related]
4. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques.
Young S; Craig P; Golzarian J
Eur Radiol; 2019 Jun; 29(6):3287-3295. PubMed ID: 30350163
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.
Tsochatzis EA; Fatourou E; O'Beirne J; Meyer T; Burroughs AK
World J Gastroenterol; 2014 Mar; 20(12):3069-77. PubMed ID: 24695579
[TBL] [Abstract][Full Text] [Related]
6. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Shin SW
Korean J Radiol; 2009; 10(5):425-34. PubMed ID: 19721826
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.
Cheng AL; Amarapurkar D; Chao Y; Chen PJ; Geschwind JF; Goh KL; Han KH; Kudo M; Lee HC; Lee RC; Lesmana LA; Lim HY; Paik SW; Poon RT; Tan CK; Tanwandee T; Teng G; Park JW
Liver Int; 2014 Feb; 34(2):174-83. PubMed ID: 24251922
[TBL] [Abstract][Full Text] [Related]
9. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Kudo M; Arizumi T
Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
11. Re: Safety and Efficacy of 70-150 µm and 100-300 µm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma.
Tu J; Jia Z; Jiang G
J Vasc Interv Radiol; 2015 Aug; 26(8):1251. PubMed ID: 26210251
[No Abstract] [Full Text] [Related]
12. Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma.
Ha TY; Hwang S; Lee YJ; Kim KH; Ko GY; Ii Gwon D; Ahn CS; Moon DB; Song GW; Jung DH; Lee HC; Lim YS; Kim KM; Shim JH; Choi JH; Lee SG
World J Surg; 2016 May; 40(5):1200-10. PubMed ID: 26666422
[TBL] [Abstract][Full Text] [Related]
13. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
Woo HY; Heo J
Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
16. Transarterial therapies for hepatocellular carcinoma.
Sangro B; D'Avola D; Iñarrairaegui M; Prieto J
Expert Opin Pharmacother; 2011 May; 12(7):1057-73. PubMed ID: 21470073
[TBL] [Abstract][Full Text] [Related]
17. TACE versus TAE as therapy for hepatocellular carcinoma.
Pleguezuelo M; Marelli L; Misseri M; Germani G; Calvaruso V; Xiruochakis E; Manousou P; Burroughs AK
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1623-41. PubMed ID: 18925854
[TBL] [Abstract][Full Text] [Related]
18. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience.
Kora S; Urakawa H; Mitsufuji T; Osame A; Higashihara H; Yoshimitsu K
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1023-9. PubMed ID: 23238851
[TBL] [Abstract][Full Text] [Related]
19. [Acute renal failure as a complication of transarterial chemoembolization in a patient with hepatocellular carcinoma].
La Spada E; La Spada M; Brusca T; Campagna ME; Di Gesaro V; Terranova A; Sandonato L; Soresi M
Recenti Prog Med; 2007 Apr; 98(4):232-5. PubMed ID: 17547360
[TBL] [Abstract][Full Text] [Related]
20. Chemoembolization of hepatocellular carcinoma--what to tell the skeptics: review and meta-analysis.
Ramsey DE; Geschwind JF
Tech Vasc Interv Radiol; 2002 Sep; 5(3):122-6. PubMed ID: 12524642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
